Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility Study

European Urology

Volumn 44, Issue 5, 2003, Pages 505-511

  Albrecht, Walter ^a   Collette, Laurence ^b   Fava, Cesare ^c   Kariakine, Oleg B ^d   Whelan, Peter ^g   Studer, Urs E ^e   De Reijke, Theo M ^f   Kil, Paul J ^g   Rea, Lesley A ^g  

^a Rudolfstiftung   (Austria)

^b EORTC DATA CENTER   (Belgium)

^c Ospidale Macchi   (Italy)

^d MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^e UNIVERSITY OF BERN   (Switzerland)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g NONE

Author keywords

Intermittent therapy; Prostate cancer

Indexed keywords

ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; METASTASIS; MULTICENTER STUDY; PAIN ASSESSMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE TUMOR; TREATMENT OUTCOME;

EID: 0142228727     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00375-0     Document Type: Article

References (17)

1. Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate 1987;11:41-50.
2. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82.
3. Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987;137:785-8.
4. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1977;37:82-94.
5. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993;71:2782-90.
6. Russo P, Liguori G, Heston WDW, Huryk R, Yang CR, Fair WR, et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 1987;47:5967-70.
7. Buhler KR, Santucci RA, Royai RA, Whitney SC, Vassella RL, Lange PH, et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograph model. Prostate 2000;43:63-70.
8. Klotz LH, Herr HW, Morse MH, Whitmore WF. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-50.
9. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999;53:530-4.
10. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottacchini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
11. Matzkin H, Eber P, Todd B, Van der Zwaag R, Soloway MS. Prognostic signifficance of changes in prostate-specific markers after endocrine treatment of Stage D2 prostatic cancer. Cancer 1992;70:2302-9.
12. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-45.
13. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonaly treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991;145:802-6.
14. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, et al. Mitomycin C in the treatment of prostate cancer: report of an EORTC Phase II study. World J Urol 1986;4:182-5.
15. Oefelein MG. Time to normalisation of serum testerone after 3-month LHRH agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685-8.
16. Kozlowski JM, Ellis WJ, Grayhack TJ. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin N Amer 1991;18:15-24.
17. Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, et al. Total androgen ablation: Canadian Experience. Urol Clin N Amer 1991;18:75-82.